Recent price: 3.79$
P/E Ratio: -
3 months Target Price: See full free report

Company Description
MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Their lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Recommendation
This company showed poor financial results for the 4th quarter and also they received a very disappointing reply from the FDA provided concerning their flagship AFREZZA drug. They came really short of analysts expectations but this seems to be a great occasion to accumulate common stock in this company. Call option contracts also seem to be undervalued for this company.

For the complete report, please visit:
http://www.investingconsultantresearch.com/2011/02/mannk ...

© 2010 Investing Consultant Research.Com